7M3I

Structure of SARS-CoV-2 spike protein receptor binding domain in complex with a neutralizing antibody, CV2-75 Fab

7M3I の概要

• エントリーDOI: 10.2210/pdb7m3i/pdb
• 分子名称: CV2-75 Fab Heavy chain, CV2-75 Fab Light chain, Spike protein S1, ... (5 entities in total)
• 機能のキーワード: sars-cov-2, covid-19, antibody, immune system, immune system-viral protein complex, immune system/viral protein
• 由来する生物種: Homo sapiens; 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 155677.24

構造登録者

Hurlburt, N.K.,Pancera, M. (登録日: 2021-03-18, 公開日: 2021-05-12, 最終更新日: 2024-10-16)

主引用文献

Jennewein, M.F.,MacCamy, A.J.,Akins, N.R.,Feng, J.,Homad, L.J.,Hurlburt, N.K.,Seydoux, E.,Wan, Y.H.,Stuart, A.B.,Edara, V.V.,Floyd, K.,Vanderheiden, A.,Mascola, J.R.,Doria-Rose, N.,Wang, L.,Yang, E.S.,Chu, H.Y.,Torres, J.L.,Ozorowski, G.,Ward, A.B.,Whaley, R.E.,Cohen, K.W.,Pancera, M.,McElrath, M.J.,Englund, J.A.,Finzi, A.,Suthar, M.S.,McGuire, A.T.,Stamatatos, L.
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects.
Cell Rep, 36:109353-109353, 2021

PubMed Abstract: SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and caused widespread disease in the past two decades. The development of a universal human coronavirus vaccine could prevent future pandemics. We characterize 198 antibodies isolated from four COVID-19+ subjects and identify 14 SARS-CoV-2 neutralizing antibodies. One targets the N-terminal domain (NTD), one recognizes an epitope in S2, and 11 bind the receptor-binding domain (RBD). Three anti-RBD neutralizing antibodies cross-neutralize SARS-CoV-1 by effectively blocking binding of both the SARS-CoV-1 and SARS-CoV-2 RBDs to the ACE2 receptor. Using the K18-hACE transgenic mouse model, we demonstrate that the neutralization potency and antibody epitope specificity regulates the in vivo protective potential of anti-SARS-CoV-2 antibodies. All four cross-neutralizing antibodies neutralize the B.1.351 mutant strain. Thus, our study reveals that epitopes in S2 can serve as blueprints for the design of immunogens capable of eliciting cross-neutralizing coronavirus antibodies.

PubMed: 34237283
DOI: 10.1016/j.celrep.2021.109353

実験手法

X-RAY DIFFRACTION (2.8 Å)